drugset / Trial / NCT04819243
PALbociclib Endocrine Therapy Followed by Talazo Vs. Talazoz-Atezo Study
RandomizedParallel-groupOpen-labelTreatment
Summary
This study is a prospective, two-arm, randomized phase II study of talazoparib versus talazoparib plus atezolizumab in ER+ premeonopausal women with metastatic breast cancer harboring HRD scar 1st line treatment: GnRH agonist + Aromatase Inhibitor(AI) + Palbociclib 28 days after the last treatment of 1st line treatment(., randomization for 2nd line treatment is conducte to arm A(Talazoparib+Atezolizumab) and arm B(Talazoparib monotherapy)
Timeline
- Start
- 2021-08-25
- Primary completion
- 2025-12-30
- Completion
- 2027-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atezolizumab | Monoclonal antibody | 1200 mg | Intravenous |
| Subject | Talazoparib | Small molecule | 1 mg | Oral |
| Background | Palbociclib | Small molecule | 125 mg | Oral |